<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683926</url>
  </required_header>
  <id_info>
    <org_study_id>Omni-Pain-103</org_study_id>
    <secondary_id>R44DA046316</secondary_id>
    <nct_id>NCT04683926</nct_id>
  </id_info>
  <brief_title>A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects</brief_title>
  <official_title>A Phase 1 Randomized Single Oral Dose Cross-Over Study Investigating Desmetramadol Dose Proportionality And Food Effect In Normal Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syntrix Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Syntrix Biosystems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate in healthy human subjects how much desmetramadol&#xD;
      (Omnitram) gets in the blood after different oral doses are taken with or without food.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, balanced, single-dose, four-treatment, four-period, four-sequence&#xD;
      (using a Williams' square design) cross-over study with each dose separated by &gt;3 days. There&#xD;
      are 4 sequences (Sequence 1, Sequence 2, Sequence 3, and Sequence 4), and 4 Periods (Period&#xD;
      I, Period II, Period III, and Period IV). Sequence 1 order is 30 mg dose with food (Period&#xD;
      I); 30 mg dose fasted (Period II), 20 mg dose fasted (Period III), and 20 mg dose fasted&#xD;
      (Period IV). Sequence 2 order is 10 mg dose fasted (Period I); 30 mg dose with food (Period&#xD;
      II), 20 mg dose fasted (Period III), and 30 mg dose fasted (Period IV). Sequence 3 order is&#xD;
      20 mg dose fasted (Period I); 10 mg dose fasted (Period II), 30 mg dose fasted (Period III),&#xD;
      and 30 mg dose with food (Period IV). Sequence 4 order is 30 mg dose fasted (Period I); 20 mg&#xD;
      dose fasted (Period II), 30 mg dose with food (Period III), and 10 mg dose fasted (Period&#xD;
      IV).&#xD;
&#xD;
      To account for potential dropouts, up to 32 eligible subjects will be randomized to obtain a&#xD;
      target sample of 24 subjects with PK responses at each of the four treatment periods (based&#xD;
      on our completed phase 1 study in 43 subjects, dropouts are unlikely (~5%); see Section&#xD;
      1.2.2). Before each oral dose, subjects will be fasted overnight for at least 10 hours.&#xD;
      Treatment sequences will include the following four unblinded single-dose oral treatments: 1)&#xD;
      desmetramadol 1 x 10 mg tablet; 2) desmetramadol 2 x 10 mg tablets; 3) desmetramadol 3 x 10&#xD;
      mg tablets; and 4) desmetramadol 3 x 10 mg tablets following a high-fat, high-calorie&#xD;
      breakfast served approximately 30 minutes before dosing and entirely consumed within 20&#xD;
      minutes. All subjects will fast for an additional four hours after desmetramadol&#xD;
      administration. The fed treatment should be administered the Omnitram dose approximately30&#xD;
      minutes after the start of the meal. Desmetramadol will be administered with approximately&#xD;
      240 ml of water. No water is allowed one hour before and one hour after each desmetramadol&#xD;
      administration.&#xD;
&#xD;
      This will be an inpatient study. Subjects will be admitted to the clinical pharmacology unit&#xD;
      on Study Day -1, and administered a single oral dose treatment on Study Day 1, Study Day 4,&#xD;
      Study Day 7 and Study Day 10. After completing study procedures on Day 11 the subject will be&#xD;
      discharged from the facility.&#xD;
&#xD;
      Blood specimens for plasma preparation and PK analysis will be collected at the following&#xD;
      times: pre-dose (0 h), and post-dose 0.5, 1.0, 1.5, 2.0, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24,&#xD;
      and 32 h.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Actual">January 18, 2021</completion_date>
  <primary_completion_date type="Actual">January 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>An open-label, randomized, balanced, single-dose, four-treatment, four-period, four-sequence (using a Williams' square design) cross-over study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Dose Pharmacokinetics</measure>
    <time_frame>32 hours</time_frame>
    <description>Study drug plasma concentrations are assessed using specimens collected immediately before and after a single dose of desmtramadol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment).</measure>
    <time_frame>Participant report adverse events throughout study enrolment; investigators observe adverse events during all 11 days of inpatient treatment; laboratory safety labs are obtained on Day 11 (the final study day).</time_frame>
    <description>Adverse events will include: 1) reports by participants; 2) observations by investigators; and 3) abnormal laboratory safety test results.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Desmetramadol 10 mg, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>While fasting a single oral dose of 10 mg desmetramadol under.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmetramadol 20 mg, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>While fasting a single oral dose of 20 mg desmetramadol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmetramadol 30 mg , fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>While fasting a single oral dose of 30 mg desmetramadol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmetramadol 30 mg , fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After feeding a single oral dose of 30 mg desmetramadol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmetramadol</intervention_name>
    <description>Analgesic</description>
    <arm_group_label>Desmetramadol 10 mg, fasted</arm_group_label>
    <arm_group_label>Desmetramadol 20 mg, fasted</arm_group_label>
    <arm_group_label>Desmetramadol 30 mg , fasted</arm_group_label>
    <arm_group_label>Desmetramadol 30 mg , fed</arm_group_label>
    <other_name>Omnitram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females with vital signs as follows at screening: systolic blood&#xD;
             pressure &gt; 90 mm Hg and &lt; 140 mm Hg; diastolic blood pressure &gt; 40 mm Hg and &lt; 90 mm&#xD;
             Hg; pulse 40 to 99 beats per minute; respiratory rate 12 to 24 breathes per minute.&#xD;
&#xD;
          2. Age 19 to 55 years.&#xD;
&#xD;
          3. Able and willing to give informed consent&#xD;
&#xD;
          4. Able to comply with all study procedures.&#xD;
&#xD;
          5. If female, must not be of childbearing potential or must agree to use one or more of&#xD;
             the following forms of contraception from screening, throughout the study and for 30&#xD;
             days following study drug administration: hormonal (e.g., oral, transdermal,&#xD;
             intravaginal, implant or injection for 3 months); double barrier (e.g., condom or&#xD;
             diaphragm with spermicide); intrauterine device (IUD) or system (IUS) (for 3 months);&#xD;
             vasectomized partner (6 months minimum); or abstinence.&#xD;
&#xD;
             Screening laboratory results must be within normal range per clinical research unit:&#xD;
             serum sodium, potassium, calcium, BUN, creatinine, ALT, AST, total bilirubin, alkaline&#xD;
             phosphatase, glucose (random), albumin, total protein, WBC and differential,&#xD;
             hemoglobin, and platelets. In addition PT and PTT must be &lt; 1.2 ULN.&#xD;
&#xD;
          6. Electrocardiogram (ECG) without clinically significant abnormalities.&#xD;
&#xD;
             Urinalysis demonstrating &lt; +1 glucose, and +1 protein.&#xD;
&#xD;
          7. If female, must have a negative pregnancy test at screening&#xD;
&#xD;
          8. Negative urine test for substances of abuse, including opiates, per clinical&#xD;
             pharmacology unit standards at screening and clinic check-in.&#xD;
&#xD;
          9. Negative serology tests for HIV, hepatitis B surface antigen, and hepatitis C virus&#xD;
             antibody.&#xD;
&#xD;
         10. Weight &gt; 50 Kg and a body mass index (BMI) of 18.0 to 32.0 kg/m (inclusive).&#xD;
&#xD;
         11. Non-smoker of tobacco for a minimum of the past 3 months, and negative urine continine&#xD;
             test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Oral temperature &gt; 38°C or current illness.&#xD;
&#xD;
          2. History of seizures, epilepsy, or recognized increase risk of seizure (e.g., head&#xD;
             trauma, metabolic disorders, alcohol or drug withdrawal).&#xD;
&#xD;
          3. History of cirrhosis or laboratory evidence of liver disease.&#xD;
&#xD;
          4. Having undergone gall bladder removal.&#xD;
&#xD;
          5. Use of alcohol within 24 hours of day -1 until the end of the study; and grapefruit,&#xD;
             grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice&#xD;
             or grapefruit-related juices within 7 days of study drug administration and until the&#xD;
             end of the study.&#xD;
&#xD;
          6. History of previous anaphylaxis, severe allergic reaction to tramadol, codeine, or&#xD;
             other opioid drugs.&#xD;
&#xD;
          7. Any other unstable acute or chronic disease that could interfere with the evaluation&#xD;
             of the safety of the study drug as determined by the principal Investigator in&#xD;
             dialogue with the Sponsor Medical Monitor.&#xD;
&#xD;
          8. Females must not be currently pregnant or breast feeding.&#xD;
&#xD;
          9. Unlikely to comply with the study protocol.&#xD;
&#xD;
         10. Known or suspected alcohol or drug abuse within the past 6 months.&#xD;
&#xD;
         11. Received another investigational agent within 4 weeks of Day -1, or within five&#xD;
             half-lives of Day -1, whichever is longer; or receiving any other investigational&#xD;
             agent during this study.&#xD;
&#xD;
         12. Any concurrent disease or condition that in the opinion of the investigator impairs&#xD;
             the subject's ability to complete the trial. Psychological, familial, sociological,&#xD;
             geographical or medical conditions which, in the Investigator's opinion, could&#xD;
             compromise compliance with the objectives and procedures of this protocol, or obscure&#xD;
             interpretation of the trial data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Schwab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Kahn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Syntrix Biosystems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zebala JA, Searle SL, Webster LR, Johnson MS, Schuler AD, Maeda DY, Kahn SJ. Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. J Pain. 2019 Oct;20(10):1218-1235. doi: 10.1016/j.jpain.2019.04.005. Epub 2019 Apr 18.</citation>
    <PMID>31005596</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Food effect</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

